Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
To determine the clinical effects of garlic in preventing and treatment of patients with chemotherapy related febrile neutropenia.These patients have a very high incidence of infections which are not routinely covered by the standard empiric therapy. Adding a non- toxic and possibly effective therapy may reduce the risk for infections, synergize the empiric antibiotic treatment and may lessen the need for broader spectrum and more severe side effects.
Full description
Patients eligible are randomized to receive placebo or garlic capsules after chemotherapy course and until leukocyte recovery.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
FN patients expected to have at least 5 days or more of neutropenia will be eligible for treatment with garlic compounds AST/ALT ≤ 3 times the upper limit of institutional laboratory normal.
Total bilirubin ≤ 2 times the upper limit of institutional laboratory normal.
BUN and creatinine should be ≤ 3 times the upper limit of institutional laboratory normal.
Newly diagnosed as well as previously treated patients will be eligible.
Exclusion criteria
History of clinically significant liver or kidney disease.
Patients on anti-coagulation therapy with Coumadin will be excluded because of the potential garlic interference with metabolism.
Patients receiving concomitant chemotherapeutic treatment
Primary purpose
Allocation
Interventional model
Masking
120 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
moshe e gatt, dr
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal